MARKET

CLDX

CLDX

Celldex Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

26.60
+0.75
+2.90%
Closed 16:00 05/26 EDT
OPEN
25.73
PREV CLOSE
25.85
HIGH
26.89
LOW
25.36
VOLUME
557.61K
TURNOVER
--
52 WEEK HIGH
57.20
52 WEEK LOW
25.17
MARKET CAP
1.24B
P/E (TTM)
-15.5392
1D
5D
1M
3M
1Y
5Y
Celldex Announces Acceptance Of Abstract For Barzolvolimab Phase 1b Results In Chronic Spontaneous Urticaria For Late-Breaking Presentation At The European Academy Of Allergy And Clinical Immunology (EAACI) Annual Congress 2022
Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria for Late-Breaking Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual
Benzinga · 05/19 13:26
Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria for Late-Breaking Presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2022
HAMPTON, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing the Phase 1b study of barzolvolimab (CDX-0159) in patients with antihistamine refractory chronic spontaneous urticaria (CSU...
GlobeNewswire · 05/19 13:23
Celldex Therapeutics' (NASDAQ:CLDX) investors will be pleased with their enviable 762% return over the last three years
Celldex Therapeutics, Inc. ( NASDAQ:CLDX ) shareholders have seen the share price descend 16% over the month. But that...
Simply Wall St. · 05/06 12:10
Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates
Celldex (CLDX) delivered earnings and revenue surprises of -6.52% and 76.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/05 21:55
Celldex GAAP EPS of -$0.49 misses by $0.04, revenue of $0.17M misses by $0.39M
Celldex press release (NASDAQ:CLDX): Q1 GAAP EPS of -$0.49 misses by $0.04. Revenue of $0.17M (-75.4% Y/Y) misses by $0.39M. Financial Guidance: Celldex believes that the cash, cash equivalents and
Seekingalpha · 05/05 21:42
Celldex Therapeutics Q1 EPS $(0.49) Down From $(0.42) YoY, Sales $200.00K Down From $685.00K YoY
Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(0.49) per share. This is a 16.67 percent decrease over losses of $(0.42) per share from the same period last year. The company reported $200.00 thousand
Benzinga · 05/05 20:40
-- Earnings Flash (CLDX) CELLDEX THERAPEUTICS Posts Q1 Revenue $0.2M
MT Newswires · 05/05 16:17
Amryt Pharma PLC Sponsored ADR (AMYT) Reports Q1 Loss, Tops Revenue Estimates
Amryt Pharma PLC Sponsored ADR (AMYT) delivered earnings and revenue surprises of 0% and 2.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/04 12:25
More
No Data
Learn about the latest financial forecast of CLDX. Analyze the recent business situations of Celldex Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
50.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CLDX stock price target is 64.83 with a high estimate of 68.00 and a low estimate of 59.00.
High68.00
Average64.83
Low59.00
Current 27.52
EPS
Actual
Estimate
-0.39-0.29-0.20-0.10
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 214
Institutional Holdings: 63.79M
% Owned: 136.43%
Shares Outstanding: 46.75M
TypeInstitutionsShares
Increased
61
6.66M
New
20
1.38M
Decreased
51
3.15M
Sold Out
29
1.63M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Non-Executive Chairman/Independent Director
Karen Shoos
Chief Executive Officer/President/Director
Anthony Marucci
Chief Financial Officer/Senior Vice President/Secretary
Sam Martin
Executive Vice President/Chief Scientific Officer
Tibor Keler
Senior Vice President/General Counsel
Freddy Jimenez
Senior Vice President/IR Contact Officer
Sarah Cavanaugh
Senior Vice President
Elizabeth Crowley
Senior Vice President
Margo Heath-Chiozzi
Senior Vice President
Ronald Pepin
Senior Vice President
Richard Wright
Senior Vice President
Diane Young
Independent Director
Keith Brownlie
Independent Director
Herbert Conrad
Independent Director
James Marino
Independent Director
Harry Penner
No Data
No Data
About CLDX
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in developing therapeutic monoclonal and bispecific antibodies. The Company's drug candidates include antibody-based therapeutics to improve the lives of patients with inflammatory diseases and many forms of cancer. The Company is engaged in the research and development of CDX-015, CDX-1140 and CDX-527. CDX-0159, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, has completed a Phase Ia study in healthy subjects. CDX-1140, an agonist monoclonal antibody targeted to CD40, a key activator of immune response, is being studied in a Phase I study. CDX-527 is the first candidate from Celldex's bispecific antibody platform. CDX-527 is a bispecific antibody that uses the Company's anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with blockade of the PD-L1/PD-1 pathway, and Company has initiated a Phase I study in advanced solid tumors.

Webull offers kinds of Celldex Therapeutics, Inc. stock information, including NASDAQ:CLDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLDX stock methods without spending real money on the virtual paper trading platform.